Metabolic effects of dopamine agonists treatment among patients with prolactinomas.

Abstract

Purpose: To evaluate the effect of cabergoline treatment on metabolic parameters including the Triglyceride-glucose (TyG) index in newly diagnosed patients with prolactinoma.Methods: 71 consecutive non-diabetic patients with prolactinoma were enrolled. Body mass index (BMI), blood pressure, and laboratory tests including TyG index were measured for each patient. Then, treatment with cabergoline was started for each patient and continued for 6 months. Anthropometric and laboratory tests were repeated every 3 months to evaluate the effects of cabergoline treatment. Results: At the baseline examination, the mean (SD) age, BMI, waist circumference (WC), systolic blood pressure (SBP), and diastolic blood pressure (DBP) of patients were 36.2 (10.5) years, 29.2 (5.0) kg/m2, 98.2 (13.7) cm, 115.3 (13.3) mmHg, and 71.4 (8.1) mmHg, respectively. Furthermore, men were older and had higher values for BMI, WC, SBP, and metabolic syndrome (MetS) prevalence compared to women. Cabergoline treatment significantly improved anthropometric and metabolic measures including BMI, WC, fasting plasma glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, uric acid (only among women), TyG index, and hypogonadism, while no significant change was detected in SBP and DBP. No significant change was found in Mets syndrome prevalence among women whereas the declining trend from baseline to 3-month evaluation was significant among men. Conclusion: Short-term treatment with cabergoline can significantly improve cardiovascular risk factors except for blood pressure. Moreover, the TyG index as a surrogate marker of insulin resistance decreased significantly after the reduction of prolactin by treatment. Generally, results were similar among both genders.